Roche and Hitachi High-Tech extend their 46-year partnership for advances in diagnostic testing

image credit- shutterstock

Roche announced the extension of its collaborative partnership with Hitachi High-Tech for the next decade. Bringing together the companies' expertise and track record in diagnostics innovation, engineering, and manufacturing, the renewed contract further strengthens the two companies' long-lasting partnership. Today the collaboration has resulted in an unrivalled global reach of over 84,000 installed diagnostic units worldwide.

The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients. The renewed partnership will aim to combine the engineering capabilities with cutting edge science to accelerate the availability of new diagnostic solutions for customers and patients worldwide.

Upcoming launches include the new cobas c703 & ISE neo units and cobas Mass Spec solution. The new analytical units cobas c 703 and cobas ISE neo for cobas pro integrated solutions are designed to increase potential testing capacity for labs and provide accurate and timely diagnosis for millions of patients around the world. The new cobas Mass Spec solution is designed to enable integration of fully-automated mass spectrometry into the routine lab. This can increase the accessibility and availability of this technology to more people around the world across various clinical applications.

The renewed partnership reinforces the exploration and development of new technologies to boost in-vitro diagnostic space, and deliver efficiencies in labs, support clinicians in their decision-making, and enable people to access rapid and reliable diagnostics. In addition to innovation in testing, the long-standing partnership is also highly focused on improving sustainability within diagnostics, with new-generation systems being able to reduce plastic waste by up to 80 percent.

"I am delighted that with this new agreement, Roche and Hitachi High-Tech can continue to push the boundaries of medical technology and transform patient care", commented Palani Kumaresan, Head of Roche Diagnostic Solutions.